Ann Arbor / Fukuoka / Piscataway / Carlsbad / Hialeah / Beverly / Cheshire / Logan / Indianapolis / San Jose / St. Louis / Santa Cruz / Cruz / New Orleans / Jose / Louis / Mannheim / Cambridge / /
Company
Eccles SA. / Roche Diagnostics GmbH / Cell Signaling Technology / pY845EGFR / Amersham Biosciences / Ki67 / Eli Lilly and Co. / Adobe / Beckman Coulter / MACH-NC Collaborative Group / AstraZeneca / /
Country
United Kingdom / Germany / /
Currency
pence / / /
Event
FDA Phase / /
Facility
University of Michigan / University of Michigan Laboratory Animals Maintenance Manual / National Cancer Institute of Canada Clinical Trials Group / Xiong HQ / University of Michigan Cell / University of Michigan Medical School / University of Michigan Cancer Center / / /
IndustryTerm
cancer therapy / therapy for patients with advanced pancreas cancer / antigen site / treatment of locally advanced head and neck cancer / propidium iodide solution / Treatment of pancreatic cancer / treatment of advanced head and neck cancers / serum-containing media / therapy for advanced pancreatic cancer / in vivo systems / /
MedicalCondition
gefitinib treated tumors / human tumor / excellent tumor / pancreatic tumors / dysfunction / recurrent pancreatic cancer / small-cell lung cancer / squamous-cell carcinoma / advanced pancreas cancer / non-small cell lung cancer / squamous cell carcinomas / acute mucositis / head cancers / tumor / UMSCC1 tumor / cancer / nasopharyngeal carcinoma / tumors / advanced solid tumors / subsequently evaluated tumor / relative tumor / human cancer / aggressive tumor / Human squamous cell carcinoma / neck cancers / fibrosis / squamous carcinoma / colorectal cancer / head and neck carcinoma / advanced pancreatic cancer / vivo tumor / carcinoma / J Cancer / head and neck cancer / head and neck carcinoma patrick y . chun / greater tumor / both causing significant tumor / advanced non-small-cell lung cancer / pancreatic cancer / headand-neck cancer / squamous cell carcinoma / advanced non-smallcell lung cancer / average relative tumor / /
Bradford CR / University of Michigan Laboratory Animals Maintenance Manual / University of Michigan / Mukesh K. Nyati Department of Radiation Oncology / IMC / University of Michigan Cell and Developmental Biology / American Society of Clinical Oncology / Department of Radiation Oncology / University of Michigan Cancer Center / National Cancer Institute of Canada Clinical Trials Group / National Institute of Health / University of Michigan Medical School / I2006 American Association for Cancer Research / the University of Michigan / Department of Cell and Developmental Biology / /
Person
Patrick Y. Chun / Mary A. Davis / Ann Oncol / Felix Y. Feng / Ashley M. Scheurer / Thomas E. Carey / Steven Kronenberg / Designe L. Chemotherapy / Theodore S. Lawrence / / /
Position
Head / Harari PM / Huang SM / locally advanced head / Harari PM / et al / advanced head / /
Product
cisplatin / Gemcitabine / Erbitux / Tarceva / sodium chloride / Iressa / fluorouracil / National Cancer Institute / /
ProvinceOrState
Louisiana / Michigan / /
PublishedMedium
Cancer Research / /
Technology
Radiation / X-ray / apoptosis / drug delivery / chemotherapy / treating cancer / antibodies / Biotechnology / /
Research Article Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck Carcinoma Patrick Y. Chun, Felix Y. Feng, Ashley M. Scheurer, Mary A. Davis, Theodore S. Lawrence, and Mukesh K. Nyati